Graduate Research Assistant Cornell University Taylorsville, New York
mRNA vaccines have received significant attention due to their role in combating the SARS-CoV-2 pandemic. As a platform, mRNA vaccines have been shown to elicit strong humoral and cellular immune responses with acceptable safety profiles. Despite their potential, industrial challenges have limited the global realization of the vaccine platform. Critical among these challenges are supply chain considerations, including mRNA production, cost of goods and frozen-chain distribution. Here, we assess the delivery of lipid nanoparticle-encapsulated mRNA (mRNA/LNP) vaccines using a split-dose regimen as an approach to develop mRNA dose sparing vaccine regimens with potential to mitigate mRNA supply chain challenges. Our data demonstrate that immunization by an mRNA/LNP vaccine encoding Respiratory Syncytial Virus pre-F over a nine-day period elicits comparable or superior magnitude of antibodies when compared to traditional bolus immunization of the vaccine. Our findings provide support for further investigations into the development of sustained delivery approaches for mRNA/LNP vaccines.
Learning Objectives:
Upon completion, participants will be able to evaluate the therapeutic efficacy of a dual therapy for psoriasis treatment.
Attendees will understand the implications of IL-10 and ATRA for immunotherapy and specifically in the context of psoriasis.
Participants will be able to state hallmarks of psoriasis and the effect this treatment had on psoriasis outcomes.